CKDNCT03501745
Smart-CKD/BP Study
A study testing WeChat in people with CKD, run by Affiliated Hospital of Qinghai University at 1 site in China.
Trial summary
Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- CKD
- What is being tested?
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2 participants
- Where
- 1 siteChina
- Study dates
- May 2018to May 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosis in line with the 2012 international kidney disease: improving global outcomes (kidney disease improving global out-comes, KDIGO) of chronic kidney disease diagnosis standard of hypertension diagnosis, "China Hypertension Prevention Guide 2010" diagnostic criteria;
- and will have the use of intelligent mobile phone, and a network connection;
- at the age of 18-70.
Who cannot join
- GFR<15 ml/min or start replacement therapy;
- do not understand Chinese, do not understand Chinese;
- malignant tumor patients;
- have mental illness;
- there is consciousness disorder.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Pengli Luo
Qinghai, Xining
Luo Pengli, doctor, 15297093191, 243216602@qq.com
Qian Yanlei, master, 15597398385, 2549116455@qq.com
About this study
Official title: Through Remote Management and Propaganda of Intelligent Mobile Phone, the Standard Rate of Blood Pressure Control and the Change of Renal Function Were Observed
Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
- Conditions
- CKD
- Being tested
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WeChatBehavioural
Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
| Study group | Role | What they receive |
|---|---|---|
| Management Group | Other | Not described Receives: Behavioral: WeChat |
| control group | Other | Not described Receives: Behavioral: WeChat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Control rate of blood pressure control
Average blood pressure of each patient ,thenStatistics of the number of blood pressure control standards .
Measured: 1 year
Drug compliance
Take medications according to the doctor's advice
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2018
- Study startMay 2018 (estimated)
- Primary completionNov 2018 (estimated)
- Study completionMay 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CKDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Affiliated Hospital of Qinghai University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Pengli Luo, Affiliated Hospital of Qinghai University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03501745
- Sponsor's protocol ID
- 20180330
- Status last verified
- Mar 2018
- First submitted
- 30 Mar 2018
- Last updated
- 18 Apr 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Apr 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Through Remote Management and Propaganda of Intelligent Mobile Phone, the Standard Rate of Blood Pressure Control and the Change of Renal Function Were Observed
- ClinicalTrials.gov ID
- NCT03501745
- Acronym / sponsor ID
- 20180330
- Conditions
- CKD
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 2 participants (estimated)
- Lead sponsor
- Affiliated Hospital of Qinghai UniversityUniversity, hospital or other
- Study start
- May 2018 (estimated)
- Primary completion
- Nov 2018 (estimated)
- Study completion
- May 2019 (estimated)
- First posted
- 18 Apr 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Management Group | Other | Behavioral: WeChat |
| control group | Other | Behavioral: WeChat |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- diagnosis in line with the 2012 international kidney disease: improving global outcomes (kidney disease improving global out-comes, KDIGO) of chronic kidney disease diagnosis standard of hypertension diagnosis, "China Hypertension Prevention Guide 2010" diagnostic criteria;
- and will have the use of intelligent mobile phone, and a network connection;
- at the age of 18-70.
Key exclusion criteria (5 listed)
- GFR<15 ml/min or start replacement therapy;
- do not understand Chinese, do not understand Chinese;
- malignant tumor patients;
- have mental illness;
- there is consciousness disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WeChatThrough remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed. | Behavioural | Management Group, control group |
Primary outcome
Control rate of blood pressure control
Time frame: 1 year
Average blood pressure of each patient ,thenStatistics of the number of blood pressure control standards .
Drug compliance
Time frame: 1 year
Take medications according to the doctor's advice
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Apr 2018.
- Individual participant dataSharing planned: Undecided
Related trials for CKD
Not yet recruitingPhase 2
Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM)
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
CKD, Metabolic Acidosis
Enrolling by invitationObservational study
Strategies for Proactive Health in People With Kidney Function Decline
Renal Insufficiency,Chronic, Dietary Intake Patterns
Not yet recruitingPhase 3
A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
Not yet recruitingObservational study
A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)
Type 2 Diabetes, Chronic Kidney Disease (CKD) Stages G2 to G3b
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WeChat in people with CKD, run by Affiliated Hospital of Qinghai University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Control rate of blood pressure control (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2018; AzTrials last refreshed its copy on 28 Oct 2026.